XtalPi, a leading technology company, has announced an expansion of its research collaboration with Pfizer to develop a next-generation molecular modeling platform for drug discovery. The goal of this initiative is to improve the accuracy of advanced physics-based methods using cutting-edge AI models, with the aim of optimizing the discovery and development of small molecule medicines. The collaboration builds on the success of their existing strategic partnership, which has already demonstrated superior performance in predicting small molecule geometry and binding affinity.
The new platform, called XtalPi Force Field (XFF), will be designed to support Pfizer scientists across diverse drug design and development scenarios. XtalPi will deploy its XFEP platform, which includes parameter customization and FEP calculations, to enable Pfizer to use it in their drug discovery efforts. The platform will be designed to provide improved accuracy, high-throughput speed, and a user-friendly interface.
The collaboration between XtalPi and Pfizer has the potential to transform the field of drug discovery by unlocking new possibilities and accelerating the delivery of life-changing therapies for patients worldwide. According to Dr. Jian Ma, CEO of XtalPi, Pfizer’s leadership in pharmaceutical innovation and deep scientific expertise have been invaluable in shaping the evolution of XtalPi’s AI-driven platform.
XtalPi was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT) and is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. The company provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.
The expansion of the collaboration between XtalPi and Pfizer is a significant development in the field of drug discovery, and it has the potential to lead to breakthroughs in the treatment of various diseases. With the use of advanced AI models and physics-based methods, the platform is expected to provide more accurate predictive tools and improve the efficiency of the drug discovery process. Overall, the collaboration between XtalPi and Pfizer is a promising development that could lead to the discovery of new and innovative medicines.